Table 6 Risks of death and hospitalisations: subgroup analysis in patients with renal impairment
Event | Aspart vs lispro | Glulisine vs lispro | Glulisine vs aspart |
|---|---|---|---|
Total Mortality | 0.97 [0.61, 1.54] | 0.56 [0.21, 1.50] | 0.58 [0.24, 1.40] |
CHD | 1.05 [0.70, 1.60] | 0.96 [0.51, 1.81] | 0.91 [0.55, 1.50] |
Fatal CHD | 1.17 [0.79, 1.74] | 1.04 [0.50, 2.16] | 0.89 [0.47, 1.67] |
CVD | 1.12 [0.76, 1.66] | 1.00 [0.56, 1.80] | 0.89 [0.56, 1.41] |
Fatal CVD | 1.47 [0.67, 3.26] | 0.68 [0.12, 3.84] | 0.46 [0.10, 2.19] |
Stroke | 1.32 [0.50, 3.51] | 0.64 [0.12, 3.34] | 0.49 [0.12, 2.06] |
Heart Failure | 1.03 [0.65, 1.64] | 0.65 [0.28, 1.52] | 0.63 [0.30, 1.31] |
Kidney Failure | 1.20 [0.76, 1.88] | 0.98 [0.47, 2.03] | 0.82 [0.45, 1.48] |
Hypoglycaemia | 1.46 [0.45, 4.72] | 1.33 [0.22, 8.20] | 0.91 [0.22, 3.82] |
Hyperglycaemia | 3.32 [0.46, 24.19] | N/A | N/A |